LRTX Stock Overview
Lirum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the treatment of debilitating diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Lirum Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.00 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| LRTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | n/a | 0.2% | 1.2% |
| 1Y | n/a | 7.4% | 20.5% |
Return vs Industry: Insufficient data to determine how LRTX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how LRTX performed against the US Market.
Price Volatility
| LRTX volatility | |
|---|---|
| LRTX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: LRTX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LRTX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 3 | Peter McDonald | www.lirumtx.com |
Lirum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the treatment of debilitating diseases. Its lead product candidate is LX-101, an insulin-like growth factor-1 receptor directed agent to treat patients with various cancers and autoimmune diseases, including thyroid eye disease. The company was incorporated in 2021 and is based in New York, New York.
Lirum Therapeutics, Inc. Fundamentals Summary
| LRTX fundamental statistics | |
|---|---|
| Market cap | US$101.97m |
| Earnings (TTM) | -US$2.20m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-46.3x
P/E RatioIs LRTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LRTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.20m |
| Earnings | -US$2.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LRTX perform over the long term?
See historical performance and comparison